Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies
Accumulating evidence confirmed that many dysregulated signaling pathways and aberrant genetic alterations contribute to the oncogenesis and heterogeneity of lymphoid malignancies. Therapeutically targeting dysregulating signaling pathways and their hidden oncogenic biomarkers are becoming available...
Enregistré dans:
Auteurs principaux: | , , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
KeAi Communications Co., Ltd.
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/f5257862057e4693b762c1a2147473ce |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|